Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 92 clinical trials
Ruxolitinib and Decitabine for High Risk Hematological Malignancies

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Decitabine intensified Conditioning Regimen in Patients with High Risk hematological malignancies undergoing

  • 0 views
  • 25 Jan, 2021
  • 1 location
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

death. Unfortunately, such therapy has side-effects, since even normal cells can be affected by the treatment. Both 5-azacitidine (5AZA) and decitabine (DEC) are FDA-approved to treat MDS. In this study

lenalidomide
anemia
bone marrow procedure
hemolysis
filgrastim
  • 0 views
  • 25 Aug, 2021
  • 1 location
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

This research is being done to assess the therapeutic efficacy and safety of a promising (venetoclax and decitabine) versus conventional "7+3"chemotherapy in induction young patients with acute

  • 0 views
  • 13 Mar, 2022
  • 1 location
The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

This open-label, randomized, two-arm, phase 2 study has the primary objective of comparing the ORR obtained with Chidamide+Decitabine+Camrelizumab against that obtained with Decitabine

refractory hodgkin lymphoma
cell transplantation
classical hodgkin lymphoma
lymphoma
  • 0 views
  • 24 Jan, 2021
  • 1 location
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

This is an open-label, phase 1/2 study has the primary objective of decitabine-primed tandem CART 19/20 in patients with B-NHL who were confirmed as r/r B cell Non-Hodgkin's Lymphoma.

  • 0 views
  • 14 Apr, 2022
  • 1 location
Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

This open-label, multi-cohorts, phase 1/2 study has the primary objective of comparing decitabine-primed tandem CART 19/20 solo, with decitabine-primed tandem CART 19/20 plus chidamide

  • 0 views
  • 26 Jan, 2021
  • 1 location
Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer

agent, maintenance therapy or alternative taxanes failed to demonstrate significant improvements over a standard carboplatin/taxane doublet. Decitabine (DAC), one major DNA demethylating agent

  • 0 views
  • 08 Nov, 2020
  • 1 location
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

This phase I/II trial aims to evaluate safety and efficacy of Chidamide, Decitabine and Immune checkpoint inhibitors in relapsed/refractory Non-Hodgkin Lymphoma and advanced solid tumors.

  • 0 views
  • 20 Apr, 2022
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

This is a two-stage, Phase II clinical trial for patients with relapsed or refractory Hodgkin Lymphoma. The purpose of stage I is to evaluate whether treatment with the study drug decitabine in

cell transplantation
refractory hodgkin lymphoma
chemotherapy regimen
lymphoma
  • 3 views
  • 22 Jan, 2021
  • 1 location
Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML

previous research, we will carry out the pretreatment regimen of decitabine + cytarabine in elderly patients with AML who have achieved disease treatment through induction therapy, and continue the

remission
cytarabine
umbilical cord blood transplantation
decitabine
neoadjuvant therapy
  • 0 views
  • 03 Feb, 2022
  • 1 location